Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182686 · ClinicalTrials.gov registry record · Phase 3
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 study, sponsored by Ampio Pharmaceuticals..
- Completed
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT03182686 is a Phase 3 study that has completed, run by Ampio Pharmaceuticals.. The registered enrollment target is 168 participants.
The verdict
NCT03182686, a Phase 3 study, has completed, sponsored by Ampio Pharmaceuticals..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.
Interventions
- BIOLOGICAL 4 mL injection of Ampion
- DRUG 4 mL Injection of Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2017-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03182686
The ClinicalTrials.gov registry entry for NCT03182686 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 4 mL injection of Ampion is the first listed.
NCT03182686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03182686 about?
NCT03182686 is a clinical study titled "AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee". This is a phase 3 randomized study to confirm the efficacy of an intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.
What is the current status of trial NCT03182686?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2017-06-19. Estimated completion is 2017-12-07.
What interventions are being tested in trial NCT03182686?
The interventions under investigation include: 4 mL injection of Ampion (BIOLOGICAL), 4 mL Injection of Placebo (DRUG).
Who is sponsoring clinical trial NCT03182686?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.